Biogen (BIIB) Tops Q2 EPS by $2.22, Guidance Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen (BIIB) Call Leaves Tons of Questions, Priority Review Voucher Comment is Negative - Mizuho
July 22, 2020 10:38 AM EDTMizuho Securities analyst Salim Syed weighed on Biogen (NASDAQ: BIIB) saying the Q2 calls leaves room for tons of questions and the priority review voucher comment is telling, in a negative way.
Syed commented, "The Biogen 2Q call just finished... More
